Literature DB >> 31428531

Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes.

Astero Klampatsa1, Shaun M O'Brien1, Jeffrey C Thompson1, Abhishek S Rao2, Jason E Stadanlick2, Marina C Martinez1, Maria Liousia1, Edward Cantu3, Keith Cengel4, Edmund K Moon1, Sunil Singhal2, Evgeniy B Eruslanov2, Steven M Albelda1.   

Abstract

Given the growing interest and promising preliminary results of immunotherapy in malignant pleural mesothelioma (MPM), it has become important to more fully understand the immune landscape in this tumor. This may be especially relevant in deciding who might benefit most from checkpoint blockade or agonist antibody therapy. Since the phenotype of tumor infiltrating lymphocytes (TILs) in MPM has not been fully described and their function has not been carefully assessed, we collected fresh tumor and blood from 22 patients undergoing surgical resection and analysed single cell suspensions by flow cytometry. The functionality of TILs was assessed by measurement of cytokine expression (IFN-γ) following overnight stimulation ex vivo. Results showed low numbers of CD8+ TILs whose function was either moderately or severely suppressed. The degree of TIL hypofunction did not correlate with the presence of co-existing macrophages or neutrophils, nor with expression of the inhibitory receptors PD-1, CD39 and CTLA-4. Hypofunction was associated with higher numbers of CD4 regulatory T cells (Tregs) and with expression of the inhibitory receptor TIGIT. On the other hand, presence of tissue-resident memory (Trm) cells and expression of TIM-3 on CD8+ cells were positively associated with cytokine production. However, Trm function was partially suppressed when the transcription factor Eomesodermin (Eomes) was co-expressed. Understanding the function of TILs in malignant mesothelioma may have clinical implications for immunotherapy, especially in choosing the best immunotherapy targets. Our data suggests that Treg cell blocking agents or TIGIT inhibitor antibodies might be especially valuable in these patients.

Entities:  

Keywords:  CD8+ TILs; Eomes; Mesothelioma; hypofunction; inhibitory receptors; tissue resident memory cells

Year:  2019        PMID: 31428531      PMCID: PMC6685523          DOI: 10.1080/2162402X.2019.1638211

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  45 in total

Review 1.  The Role of Regulatory T Cells in Mesothelioma.

Authors:  Demelza J Ireland; Haydn T Kissick; Manfred W Beilharz
Journal:  Cancer Microenviron       Date:  2012-02-01

2.  T-bet and eomesodermin play critical roles in directing T cell differentiation to Th1 versus Th17.

Authors:  Yu Yang; Jiangnan Xu; Yanyan Niu; Jonathan S Bromberg; Yaozhong Ding
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

3.  Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T-cell depletion in a murine mesothelioma model.

Authors:  Licun Wu; Zhihong Yun; Tetsuzo Tagawa; Katrina Rey-McIntyre; Masaki Anraku; Marc de Perrot
Journal:  J Thorac Oncol       Date:  2011-09       Impact factor: 15.609

4.  Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.

Authors:  Takashi Inozume; Ken-Ichi Hanada; Qiong J Wang; Mojgan Ahmadzadeh; John R Wunderlich; Steven A Rosenberg; James C Yang
Journal:  J Immunother       Date:  2010 Nov-Dec       Impact factor: 4.456

5.  Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.

Authors:  Michelle K Gleason; Todd R Lenvik; Valarie McCullar; Martin Felices; M Shea O'Brien; Sarah A Cooley; Michael R Verneris; Frank Cichocki; Carol J Holman; Angela Panoskaltsis-Mortari; Toshiro Niki; Mitsuomi Hirashima; Bruce R Blazar; Jeffrey S Miller
Journal:  Blood       Date:  2012-02-08       Impact factor: 22.113

6.  Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma.

Authors:  Bryan M Burt; Scott J Rodig; Tamara R Tilleman; Andrew W Elbardissi; Raphael Bueno; David J Sugarbaker
Journal:  Cancer       Date:  2011-04-26       Impact factor: 6.860

7.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

Authors:  Nicholas J Vogelzang; James J Rusthoven; James Symanowski; Claude Denham; E Kaukel; Pierre Ruffie; Ulrich Gatzemeier; Michael Boyer; Salih Emri; Christian Manegold; Clet Niyikiza; Paolo Paoletti
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

8.  Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

Authors:  Mojgan Ahmadzadeh; Laura A Johnson; Bianca Heemskerk; John R Wunderlich; Mark E Dudley; Donald E White; Steven A Rosenberg
Journal:  Blood       Date:  2009-05-07       Impact factor: 22.113

Review 9.  Molecular regulation of T-cell anergy.

Authors:  Yan Zheng; Yuanyuan Zha; Thomas F Gajewski
Journal:  EMBO Rep       Date:  2008-01       Impact factor: 8.807

10.  Combined intratumoral regulatory T-cell depletion and transforming growth factor-β neutralization induces regression of established AE17 murine mesothelioma tumors.

Authors:  Haydn T Kissick; Demelza J Ireland; Manfred W Beilharz
Journal:  J Interferon Cytokine Res       Date:  2009-04       Impact factor: 2.607

View more
  14 in total

Review 1.  Immunotherapy approaches for malignant pleural mesothelioma.

Authors:  Dean A Fennell; Sean Dulloo; James Harber
Journal:  Nat Rev Clin Oncol       Date:  2022-07-01       Impact factor: 65.011

2.  Immune checkpoint inhibitors for unresectable malignant pleural mesothelioma.

Authors:  Giulio Metro; Diego Signorelli; Elio G Pizzutilo; Laura Giannetta; Giulio Cerea; Miriam Garaffa; Alex Friedlaender; Alfredo Addeo; Martina Mandarano; Guido Bellezza; Fausto Roila
Journal:  Hum Vaccin Immunother       Date:  2021-05-18       Impact factor: 3.452

Review 3.  Malignant Pleural Effusions-A Window Into Local Anti-Tumor T Cell Immunity?

Authors:  Nicola Principe; Joel Kidman; Richard A Lake; Willem Joost Lesterhuis; Anna K Nowak; Alison M McDonnell; Jonathan Chee
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

4.  Acidosis-Induced TGF-β2 Production Promotes Lipid Droplet Formation in Dendritic Cells and Alters Their Potential to Support Anti-Mesothelioma T Cell Response.

Authors:  Natalia Trempolec; Charline Degavre; Bastien Doix; Davide Brusa; Cyril Corbet; Olivier Feron
Journal:  Cancers (Basel)       Date:  2020-05-19       Impact factor: 6.639

5.  Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity.

Authors:  Jarrod D Predina; Andrew R Haas; Marina Martinez; Shaun O'Brien; Edmund K Moon; Patrick Woodruff; Jason Stadanlick; Christopher Corbett; Lydia Frenzel-Sulyok; Mitchell G Bryski; Evgeniy Eruslanov; Charuhas Deshpande; Corey Langer; Laura K Aguilar; Brian W Guzik; Andrea G Manzanera; Estuardo Aguilar-Cordova; Sunil Singhal; Steven M Albelda
Journal:  Mol Ther       Date:  2020-11-05       Impact factor: 11.454

Review 6.  Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.

Authors:  Steven G Gray
Journal:  BMC Pulm Med       Date:  2021-05-05       Impact factor: 3.317

7.  A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab.

Authors:  Prasad S Adusumilli; Marjorie G Zauderer; Isabelle Rivière; Stephen B Solomon; Valerie W Rusch; Roisin E O'Cearbhaill; Amy Zhu; Waseem Cheema; Navin K Chintala; Elizabeth Halton; John Pineda; Rocio Perez-Johnston; Kay See Tan; Bobby Daly; Jose A Araujo Filho; Daniel Ngai; Erin McGee; Alain Vincent; Claudia Diamonte; Jennifer L Sauter; Shanu Modi; Devanjan Sikder; Brigitte Senechal; Xiuyan Wang; William D Travis; Mithat Gönen; Charles M Rudin; Renier J Brentjens; David R Jones; Michel Sadelain
Journal:  Cancer Discov       Date:  2021-07-15       Impact factor: 39.397

Review 8.  Tumor Immune Microenvironment and Genetic Alterations in Mesothelioma.

Authors:  Stefanie Hiltbrunner; Laura Mannarino; Michaela B Kirschner; Isabelle Opitz; Angelica Rigutto; Alexander Laure; Michela Lia; Paolo Nozza; Antonio Maconi; Sergio Marchini; Maurizio D'Incalci; Alessandra Curioni-Fontecedro; Federica Grosso
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

Review 9.  Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge.

Authors:  David Michael Abbott; Chandra Bortolotto; Silvia Benvenuti; Andrea Lancia; Andrea Riccardo Filippi; Giulia Maria Stella
Journal:  Cancers (Basel)       Date:  2020-05-07       Impact factor: 6.639

10.  Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.

Authors:  Astero Klampatsa; Michael S Leibowitz; Jing Sun; Maria Liousia; Evguenia Arguiri; Steven M Albelda
Journal:  Mol Ther Oncolytics       Date:  2020-07-15       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.